Meaningful Improvement in General Health Outcomes With Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results From a Phase 3 Study

For submission to: *The Patient*

Ana-Maria Orbai,[1] Laura C. Coates,[2] Atul Deodhar,[3] Philip S. Helliwell,[4] Christopher T. Ritchlin,[5] Evan Leibowitz,[6] Alexa P. Kollmeier,[7] Elizabeth C. Hsia,[7,8] Xie L. Xu,[7] Shihong Sheng,[7] Yusang Jiang,[7,9] Yan Liu,[7] Chenglong Han[7]

[1]Psoriatic Arthritis Program, Johns Hopkins University School of Medicine, Baltimore, MD, USA; [2]Nuffield Department of Orthopaedics, University of Oxford, Oxford, UK; [3]Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, USA; [4]Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; [5]Department of Medicine, Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA; [6]Janssen Scientific Affairs, LLC, Horsham, PA, USA; [7]Janssen Research & Development, Spring House, PA/San Diego CA, USA; [8]University of Pennsylvania School of Medicine, Philadelphia, PA, USA; [9]Cytel, Inc., Chesterbrook, PA, USA

Corresponding author:

Ana-Maria Orbai, MD MHS

Email: aorbai1@jhmi.edu

SUPPLEMENTARY MATERIAL

Supplementary Fig 1. Cumulative distribution of points of improvement in PROMIS-29 sleep disturbance (A), anxiety (B), and depression (C) domain T-scores from baseline to Week 24.

PROMIS, Patient-Reported Outcomes Measurement Information System; Q4W, every 4 weeks; Q8W, every 8 weeks.

Supplementary Fig 2. Proportions of patients achieving ≥3-point improvements in PROMIS-29 domain T-scores from baseline to Week 24 and Week 52 (non-responder imputation).

Week 24: All patients, including those with imputed data (patients meeting treatment failure prior to Week 24 or with missing data at Week 24 were considered as not achieving ≥5-point improvement); P-values calculated using Cochran-Mantel-Haenszel test; nominal p-values vs PBO: *p<0.05; †p<0.01; ‡p<0.001. GUS Q4W, n=128; GUS Q8W, n=127; PBO, n=126.

Week 52: Evaluable patients; after discontinuation of study agent for any reason, patients with missing data were considered non-responders.

GUS, guselkumab; PBO, placebo; PROMIS, Patient-Reported Outcomes Measurement Information System; Q4W, every 4 weeks; Q8W, every 8 weeks.